martes, 26 de enero de 2010

Liraglutide (marketed as Victoza) Information

Drug Information Update - FDA approves Victoza (liraglutide) to treat type 2 diabetes mellitus in adults

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.

FDA approved Victoza (liraglutide) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Victoza is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. Additionally, Victoza is not a substitute for insulin and should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
For more information, please visit: Victoza (see below)

Liraglutide (marketed as Victoza) Information

No hay comentarios:

Publicar un comentario